Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

22.95
+0.61002.73%
Post-market: 23.040.0944+0.41%19:42 EDT
Volume:4.08M
Turnover:94.14M
Market Cap:2.88B
PE:-12.78
High:23.57
Open:22.26
Low:22.04
Close:22.34
Loading ...

Apellis Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
5 hours ago

RBC Raises Price Target on Apellis Pharmaceuticals to $19 From $17, Keeps Sector Perform Rating

MT Newswires Live
·
Yesterday

Stock Track | Apellis Pharmaceuticals Soars 13% on Impressive Q2 Earnings Beat Despite Revenue Miss

Stock Track
·
31 Jul

Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q2 EPS Loss $0.33, vs. FactSet Est of $0.44 Loss

MT Newswires Live
·
31 Jul

Stock Track | Apellis Pharmaceuticals Surges 5.26% Pre-market on Earnings Beat Despite Revenue Miss

Stock Track
·
31 Jul

Apellis Pharmaceuticals Q2 EPS $(0.33) Beats $(0.48) Estimate, Sales $178.494M Miss $187.790M Estimate

Benzinga
·
31 Jul

Apellis price target raised to $22 from $20 at Scotiabank

TIPRANKS
·
30 Jul

Apellis Pharmaceuticals Is Maintained at Buy by Citigroup

Dow Jones
·
30 Jul

Apellis Pharmaceuticals (APLS) Receives a Buy from Cantor Fitzgerald

TIPRANKS
·
29 Jul

Apellis price target raised to $46 from $41 at Citi

TIPRANKS
·
29 Jul

Apellis Pharmaceuticals Inc : Citigroup Raises Target Price to $46 From $41

THOMSON REUTERS
·
29 Jul

Apellis Pharmaceuticals Gets FDA Approval for Kidney Disease Treatment

Dow Jones
·
29 Jul

FDA Approves Apellis Pharmaceuticals' EMPAVELI as First Treatment for C3G and Primary IC-MPGN in Patients 12 and Older

Reuters
·
29 Jul

FDA Approves Apellis’ Empaveli® (Pegcetacoplan) as the First C3g and Primary Ic-Mpgn Treatment for Patients 12 and Older

THOMSON REUTERS
·
29 Jul

Apellis Pharmaceuticals trading halted, news pending

TIPRANKS
·
29 Jul

David O. Watson, General Counsel, Reports Disposal of Apellis Pharmaceuticals Common Shares

Reuters
·
19 Jul

CEO Cedric Francois Reports Disposal of Apellis Pharmaceuticals Common Shares

Reuters
·
17 Jul

Apellis price target raised to $24 from $23 at BofA

TIPRANKS
·
16 Jul

Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy

Reuters
·
15 Jul

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL)

TIPRANKS
·
09 Jul